A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

NCT02521844 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

89

Enrollment

OTHER_GOV

Sponsor class

Conditions

Solid Tumors

Interventions

DRUG: ETC-1922159
DRUG: Pembrolizumab

Sponsor

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Collaborators

[object Object]